Document Type : Research Articles
Authors
1
Department of Nursing, Karaj Branch, Islamic Azad University, Karaj, Iran.
2
Department of Pharmaceutics, Pharmaceutical Sciences Branch, Islamic Azad University (IAU), Tehran, Iran.
3
Department of Medicine, Iran University of Medical Sciences, Tehran, Iran.
4
Department of Mechanical Engineering, Islamic Azad University, Science and Research Branch, Tehran, Iran.
5
MDDr., PhD and Specialty Student, Pavol Jozef Safarik University, Klinika Bacikova, Kosice, Slovakia.
6
Department of Neurology, School of Medicine, Boushehr University of Medical Sciences, Boushehr, Iran.
7
Department of Chemistry Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran.
8
Department of life Science, College of Life Science, National Taiwan University, Taipei, Taiwan.
Abstract
Objective: Addressing both the initial treatment response and subsequent paclitaxel resistance is a pivotal concern. Nano drug delivery, an emerging approach, presents a cutting-edge alternative to conventional chemotherapy. Methods: This investigation synthesized PEGylated nanoparticles (NPs) via the Reverse Phase Evaporation technique for liposomal NPs. Characteristics such as zeta potential, size, drug release and polydispersity index (PDI) were subjected to evaluation. Subsequently, cytotoxicity assays were conducted on gastric cancer cells (AGS) following 24 and 48-hour incubation periods. Results: In this study, the liposomal NPs had a zeta potential of -22 mV and a particle size of 285 nm. The Entrapment efficiency was determined as 41% that occurred physically. Additionally, the liposomal NPs demonstrated a high drug retention rate (39% remained after 72 hours), and they exhibited significantly increased cytotoxicity compared to the free drug, confirming their effectiveness as a suitable carrier for paclitaxel during both incubation periods (P<0.05). Conclusion: These findings collectively advocate the potential of liposomal NPs as promising contenders for effective nano-drug application in propelling chemotherapy forward.
Keywords
Main Subjects
)